Immune PAI-1 inhibitor MDI-2517 shows superior preclinical efficacy in systemic sclerosis models Dec. 3, 2024 Researchers from the University of Michigan Medical School and MDI Therapeutics Inc. recently presented preclinical data for MDI-2517.Read More
Gastrointestinal Ladon’s LDN-071 ameliorates severity in colitis models Oct. 16, 2024 Recent decades have brought advances in pharmacological therapies for treating inflammatory bowel disease (IBD), but their sustained efficacy is still not enough, and developing novel therapies is an unmet medical need for this condition.Read More
Gastrointestinal Ladon’s LDN-071 ameliorates severity in experimental colitis Feb. 29, 2024 The efficacy of anti-inflammatory therapies used for treating inflammatory bowel disease (IBD) is still not optimal.Read More
